Radiographs showing the effect of ibandronate (4 μg per mouse per day for 28 days) on osteolytic lesions (arrows) in the lumbar vertebrae of 5TGM1 myeloma-bearing mice. (A) Non–tumor-bearing control treated with PBS. (B) Non–tumor-bearing control treated with ibandronate. (C) 5TGM1 myeloma-bearing mouse treated with PBS. (D) 5TGM1 myeloma-bearing mouse treated with ibandronate. Note the large number of lesions visible in myeloma-bearing mice treated with PBS (C), which are prevented by treatment with ibandronate (D). Note also the reduction in height of the lumbar vertebrae in myeloma-bearing mice treated with PBS (C) as compared with controls (A), (B), and myeloma-bearing mice treated with ibandronate (D). There are seven vertebrae visible in the field in (C), as compared with six in (A), (B), and (D).